Clinical Trials Logo

Clinical Trial Summary

Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative care. Recently an international panel of expert have succeeded to elaborate dedicated recommendations for cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) in a two-part series of guidelines based on expert consensus (Hübner et al., EJSO, 2020). The aim of this prospective validation study was therefore to study acceptance, feasibility and clinical results of these guidelines in clinical practice. Hypothesis of the study: Introduction of ERAS® guidelines is feasible and safe. Increasing compliance with ERAS® guidelines (after implementation) will improve recovery and early clinical outcomes of patients undergoing CRS/HIPEC.


Clinical Trial Description

The study includes two succesive phases interrupted by a stage to implement ERAS® guidelines. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05185791
Study type Observational
Source Hospices Civils de Lyon
Contact Olivier Glehen, MD, PhD
Phone +33 478 862 371
Email [email protected]
Status Recruiting
Phase
Start date October 1, 2021
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT00369096 - Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina) Phase 2
Active, not recruiting NCT02973750 - Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
Completed NCT04125160 - Glycaemic Markers in Persons With Type 2 Diabetes on Peritoneal Dialysis
Recruiting NCT03150992 - EDMONd - Elemental Diet in Bowel Obstruction N/A